曼恩凯德生物医疗 MNKD 深 沪
等待开盘 09-17 09:30:00 美东时间
5.37
-0.010
-0.19%
华盛通- 最 高5.40
- 今 开5.39
- 成交量 311.68万股
- 最 低 5.25
- 昨 收 5.38
- 总市值 16.32亿
- 52周最高 7.63
- 市盈率 静 55.25
- 换手率 1.03%
- 52周最低 3.3812
- 委 比 -85.19%
- 总股本 3.04亿
- 历史最高 57.40
- 量 比 0.71
- 振 幅 2.79%
- 历史最低 0.666
- 每 手 1
- 风险率 1.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股机会日报 | 垄断案获重大胜利，谷歌盘前涨超5%；金价站上3600美元续创历史新高
垄断案获重大胜利，谷歌盘前涨超5%；金价站上3600美元续创历史新高！加密货币再获利好，美国SEC、CFTC称支持交易所交易现货加密资产>>
09-03 19:58
美股牛股 | 医药股彻底疯狂！美国联合医疗飙升近33%，新药迎重大进展；Ionis制药涨近35%
医药股彻底疯狂！美国联合医疗飙升近33%，新药迎重大进展；Ionis制药涨近35%，实验性药物临床数据乐观；MLYS大涨逾80%，高血压新药市场前景广阔>>
09-03 15:53
美股大行评级 | 潜在涨幅91.64%！曼恩凯德生物医疗获HC Wainwright升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持曼恩凯德生物医疗"买入"评级，目标价从9美元升至11美元；杰富瑞：维持Ionis Pharmaceuticals"买入"评级，目标价从83美元升至96美元
09-03 10:20
HC Wainwright & Co. Maintains Buy on MannKind, Raises Price Target to $11
HC Wainwright & Co. analyst Brandon Folkes maintains MannKind (NASDAQ:MNKD) with a Buy and raises the price target from $9 to $11.
09-03 00:16
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling over 250 points on Tue...
09-02 22:41
华兴资本医疗与生命科技行业周报【Vol.382】
来源：华兴资本 “华兴资本医疗与生命科技行业周报”定期发布，专注从资本角度解读一周数据，并提供最新行业观察。 医疗与生命科技是华兴资本多年来关注并深耕的领域，目...
09-01 08:30
MannKind Amends License Agreement with United Therapeutics
MannKind ( ($MNKD) ) just unveiled an announcement. On August 24, 2025, MannKin...
08-27 20:28
MannKind to Present at Upcoming Investor Conferences
<p>MannKind Corporation (Nasdaq: MNKD) announced its participation in several upcoming investor conferences. CEO Michael Castagna and CFO Chris Prentiss will present updates at the Wells Fargo Health Care Conference in Boston on September 3, the Cantor Global Healthcare Conference in New York on September 4, the H.C. Wainwright Global Investment Conference in New York on September 9, and the Morgan Stanley Global Healthcare Conference in New York...
08-27 20:05
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
<p><em>Initial collaboration led to Tyvaso DPI®, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension.</em> MannKind Corporation and United Therapeutics Corporation have expanded their partnership to develop a second dry powder inhalation therapy. Under the agreement, MannKind will formulate a new molecule using its proprietary Technosphere® platform, while United Therapeutics will handle preclinical and clinical deve...
08-27 12:05
美股大行评级 | 潜在涨幅17.9%！Stifel维持英伟达"买入"评级，目标价升至212美元；美银首予Figma"中性"评级，目标价85美元
今日重点评级关注：Stifel：维持英伟达"买入"评级，目标价从202美元升至212美元；蒙特利尔银行：维持Sabra Health Care REIT"与大市齐平"评级，目标价从19美元升至22美元
08-26 10:29
